Scholarlink

<p><i>H. pylori</i> induces gastritis and promotes gastric carcinogenesis. Antimicrobial therapy against <i>H. pylori</i> often causes gastrointestinal dysbiosis, with side effects like vomiting, diarrhea, and antibiotic resistance, hindering effective eradication. This study investigated the effects and mechanisms of probiotics in balancing microbiota to alleviate <i>H. pylori</i>-related gastritis. Using in vivo and in vitro gastritis models with various <i>H. pylori</i> virulence strains, the study employed <i>16S rRNA</i> amplicon sequencing and qPCR to link gastric microbiota with inflammation. Genomic mining and microbiota reconstruction identified <i>Lactococcus garvieae</i> LG3092 and GarQ as key microecological-targeting regulators. Results showed that different <i>H. pylori</i> induce varying levels of gastritis in vivo, with elevated IL-1β, IL-6, and TNF-α levels linked to pro-inflammatory bacteria. LG3092 secretes GarQ, specifically targeting Man-PTS receptors on pro-inflammatory bacteria, disrupting their membranes and modulating the gastric microbiota, highlighting the potential of probiotics in combination with other therapies to managing <i>H. pylori</i> infection and related gastritis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Garvicin Q-producing Lactococcus garvieae LG3092: its role in mitigating dysbiosis and H. pylori-associated gastritis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月28日

查看全文
  • Yanyan Shang,
  • Yuwei Wu,
  • Ying Zhang,
  • Xinyu Zhao,
  • Juan Wang,
  • Yu Ding,
  • Hui Zhao,
  • Moutong Chen,
  • Ying Li,
  • Qingping Wu

摘要

H. pylori induces gastritis and promotes gastric carcinogenesis. Antimicrobial therapy against H. pylori often causes gastrointestinal dysbiosis, with side effects like vomiting, diarrhea, and antibiotic resistance, hindering effective eradication. This study investigated the effects and mechanisms of probiotics in balancing microbiota to alleviate H. pylori-related gastritis. Using in vivo and in vitro gastritis models with various H. pylori virulence strains, the study employed 16S rRNA amplicon sequencing and qPCR to link gastric microbiota with inflammation. Genomic mining and microbiota reconstruction identified Lactococcus garvieae LG3092 and GarQ as key microecological-targeting regulators. Results showed that different H. pylori induce varying levels of gastritis in vivo, with elevated IL-1β, IL-6, and TNF-α levels linked to pro-inflammatory bacteria. LG3092 secretes GarQ, specifically targeting Man-PTS receptors on pro-inflammatory bacteria, disrupting their membranes and modulating the gastric microbiota, highlighting the potential of probiotics in combination with other therapies to managing H. pylori infection and related gastritis.